Publication Details

Category Text Publication
Reference Category Journals
DOI 10.1002/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z
Title (Primary) Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma
Author Trefzer, U.; Weingart, G.; Chen, Y.W.; Herberth, G. ORCID logo ; Adrian, K.; Winter, H.; Audring, H.; Guo, Y.J.; Sterry, W.; Walden, P.
Source Titel International Journal of Cancer
Year 2000
Department IMMU
Volume 85
Issue 5
Page From 618
Page To 626
Language englisch
Abstract Hybrid cell vaccination is a new cancer immune therapy approach that aims at recruiting T cell help for the induction of tumour specific cytolytic immunity. The vaccines are generated by fusion of the patients' tumour cells with allogeneic MHC class II bearing cells to combine the tumour's antigenicity with the immunogenicity of allogeneic MHC molecules. Safety and anti-tumour activity of this treatment were assessed in a clinical trial that has yielded one complete and one partial remission, and 5 cases of stable disease among 16 patients with advanced stage metastatic melanoma. As evidenced by histology, the vaccination induced T cell relocation into tumour nodules. Stable disease could be maintained by repeated booster injections for more than 24 months in some patients. The side effects were minor. Occasional occurrences of vitiligo spots after vaccination were indicative of a restricted therapy induced auto-immune reactivity. The results suggest that hybrid cell vaccination is a safe cancer immune therapy potentially effective for induction of acute anti-tumour response as well as long-term maintenance. Int. J. Cancer 85:618-626, 2000.
Persistent UFZ Identifier https://www.ufz.de/index.php?en=20939&ufzPublicationIdentifier=7705
Trefzer, U., Weingart, G., Chen, Y.W., Herberth, G., Adrian, K., Winter, H., Audring, H., Guo, Y.J., Sterry, W., Walden, P. (2000):
Hybrid cell vaccination for cancer immune therapy: First clinical trial with metastatic melanoma
Int. J. Cancer 85 (5), 618 - 626 10.1002/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z